Publicaciones (85) Publicaciones de MARIA DOLORES MOLTO RUIZ

2024

  1. Accelerated Cortical Thinning in Schizophrenia Is Associated With Rare and Common Predisposing Variation to Schizophrenia and Neurodevelopmental Disorders

    Biological Psychiatry

2023

  1. Common genetic variants contribute to heritability of age at onset of schizophrenia

    Translational Psychiatry, Vol. 13, Núm. 1

  2. Correction: Common genetic variants contribute to heritability of age at onset of schizophrenia (Translational Psychiatry, (2023), 13, 1, (201), 10.1038/s41398-023-02508-0)

    Translational Psychiatry

  3. Recent natural selection conferred protection against schizophrenia by non-antagonistic pleiotropy

    Scientific Reports, Vol. 13, Núm. 1

  4. The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case–control study

    Social Psychiatry and Psychiatric Epidemiology, Vol. 58, Núm. 10, pp. 1573-1580

2022

  1. A polygenic approach to the association between smoking and schizophrenia

    Addiction Biology, Vol. 27, Núm. 1

  2. Biotecnologia per a periodistes: un esforç gratificant

    Vint anys de periodisme a la Universitat de València: aproximació testimonial d'una experiència de servei públic del segle XXI (Universidad de Valencia = Universitat de València), pp. 267-270

  3. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

  4. Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia

    Nature Communications, Vol. 13, Núm. 1

2021

  1. FOXP2 expression and gray matter density in the male brains of patients with schizophrenia

    Brain Imaging and Behavior, Vol. 15, Núm. 3, pp. 1403-1411

  2. The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis

    Psychopharmacology, Vol. 238, Núm. 3, pp. 665-676

2020

  1. Antioxidant therapies and oxidative stress in friedreich´s ataxia: The right path or just a diversion?

    Antioxidants, Vol. 9, Núm. 8, pp. 1-23

2019

  1. Drosophila as a model system for the identification of pharmacological therapies in neurodegenerative diseases

    Insights into Human Neurodegeneration: Lessons Learnt from Drosophila (Springer Singapore), pp. 433-467

  2. FOXP2 and language alterations in psychiatric pathology

    Salud mental, Vol. 42, Núm. 6, pp. 299-308

  3. Phosphodiesterase Inhibitors Revert Axonal Dystrophy in Friedreich’s Ataxia Mouse Model

    Neurotherapeutics, Vol. 16, Núm. 2, pp. 432-449

  4. The role of iron in Friedreich's ataxia: Insights from studies in human tissues and cellular and animal models

    Frontiers in Neuroscience, Vol. 13, Núm. FEB

  5. Time dependent expression of the blood biomarkers EIF2D and TOX in patients with schizophrenia

    Brain, Behavior, and Immunity, Vol. 80, pp. 909-915

2018

  1. Affective versus first-episode non-affective first-episode psychoses: A longitudinal study

    Journal of Affective Disorders, Vol. 238, pp. 297-304

  2. Drosophila melanogaster models of friedreich's ataxia

    BioMed Research International, Vol. 2018

2017

  1. Drosophila melanogaster models of metal-related human diseases and metal toxicity

    International Journal of Molecular Sciences, Vol. 18, Núm. 7